INTRODUCTION: Transdermal analysis patches (TAPs) noninvasively measure soluble proteins in the stratum corneum. Ultimately, such local protein profiles could benefit the search for biomarkers to improve personalized treatment in psoriasis. This study aimed to explore the patient friendliness and protein detection by TAP in pediatric psoriasis in daily clinical practice. METHODS: In this observational study, TAPs measuring CXC chemokine ligand (CXCL)-1/2, CC chemokine ligand (CCL)-27, interleukin (IL)-1RA, IL-23, IL-1α, IL-8, IL-4, IL-22, IL-17A, vascular endothelial growth factor (VEGF), human beta-defensin (hBD)-2, hBD-1, and kallikrein-related peptidase (KLK)-5 were applied on lesional, peri-lesional, and non-lesional skin sites of psoriasis patients aged >5 to <18 years. Discomfort during TAP removal as an indicator for patient friendliness was assessed by visual analogue scale (VAS; range 0-10). RESULTS: Thirty-two patients (median age 14.0 years) were included, of which 19 were treated with solely topical agents and 13 with systemic treatment. The median VAS of discomfort during TAP removal was 1.0 (interquartile range 1.0). Significantly higher levels in lesional versus non-lesional skin were found for IL-1RA, VEGF, CXCL-1/2, hBD-2, and IL-8, whereas lower levels were found for IL-1α. Skin surface proteins were measured in both treatment groups, with significant higher lesional levels of KLK-5, IL-1RA, hBD-2, IL-1α, IL-23, and CCL-27 in the systemic treatment group. CONCLUSION: The TAP platform holds the potential for patient-friendly and noninvasive monitoring of skin-derived proteins in pediatric psoriasis patients in daily clinical practice.
INTRODUCTION: Transdermal analysis patches (TAPs) noninvasively measure soluble proteins in the stratum corneum. Ultimately, such local protein profiles could benefit the search for biomarkers to improve personalized treatment in psoriasis. This study aimed to explore the patient friendliness and protein detection by TAP in pediatric psoriasis in daily clinical practice. METHODS: In this observational study, TAPs measuring CXC chemokine ligand (CXCL)-1/2, CC chemokine ligand (CCL)-27, interleukin (IL)-1RA, IL-23, IL-1α, IL-8, IL-4, IL-22, IL-17A, vascular endothelial growth factor (VEGF), human beta-defensin (hBD)-2, hBD-1, and kallikrein-related peptidase (KLK)-5 were applied on lesional, peri-lesional, and non-lesional skin sites of psoriasis patients aged >5 to <18 years. Discomfort during TAP removal as an indicator for patient friendliness was assessed by visual analogue scale (VAS; range 0-10). RESULTS: Thirty-two patients (median age 14.0 years) were included, of which 19 were treated with solely topical agents and 13 with systemic treatment. The median VAS of discomfort during TAP removal was 1.0 (interquartile range 1.0). Significantly higher levels in lesional versus non-lesional skin were found for IL-1RA, VEGF, CXCL-1/2, hBD-2, and IL-8, whereas lower levels were found for IL-1α. Skin surface proteins were measured in both treatment groups, with significant higher lesional levels of KLK-5, IL-1RA, hBD-2, IL-1α, IL-23, and CCL-27 in the systemic treatment group. CONCLUSION: The TAP platform holds the potential for patient-friendly and noninvasive monitoring of skin-derived proteins in pediatric psoriasis patients in daily clinical practice.
Authors: H Dickel; A Goulioumis; T Gambichler; J W Fluhr; J Kamphowe; P Altmeyer; O Kuss Journal: Skin Pharmacol Physiol Date: 2010-05-18 Impact factor: 3.479
Authors: Nick Dand; Michael Duckworth; David Baudry; Alice Russell; Charles J Curtis; Sang Hyuck Lee; Ian Evans; Kayleigh J Mason; Ali Alsharqi; Gabrielle Becher; A David Burden; Richard G Goodwin; Kevin McKenna; Ruth Murphy; Gayathri K Perera; Radu Rotarescu; Shyamal Wahie; Andrew Wright; Nick J Reynolds; Richard B Warren; Christopher E M Griffiths; Catherine H Smith; Michael A Simpson; Jonathan N Barker Journal: J Allergy Clin Immunol Date: 2018-12-20 Impact factor: 10.793
Authors: Emma Guttman-Yassky; Aisleen Diaz; Ana B Pavel; Marie Fernandes; Rachel Lefferdink; Taylor Erickson; Talia Canter; Stephanie Rangel; Xiangyu Peng; Randall Li; Yeriel Estrada; Hui Xu; James G Krueger; Amy S Paller Journal: JAMA Dermatol Date: 2019-12-01 Impact factor: 10.282
Authors: Patrick A M Jansen; Diana Rodijk-Olthuis; Edward J Hollox; Marijke Kamsteeg; Geuranne S Tjabringa; Gys J de Jongh; Ivonne M J J van Vlijmen-Willems; Judith G M Bergboer; Michelle M van Rossum; Elke M G J de Jong; Martin den Heijer; Andrea W M Evers; Mieke Bergers; John A L Armour; Patrick L J M Zeeuwen; Joost Schalkwijk Journal: PLoS One Date: 2009-03-06 Impact factor: 3.240
Authors: Frank Kolbinger; Christian Loesche; Marie-Anne Valentin; Xiaoyu Jiang; Yi Cheng; Philip Jarvis; Thomas Peters; Claudio Calonder; Gerard Bruin; Florine Polus; Birgit Aigner; David M Lee; Manfred Bodenlenz; Frank Sinner; Thomas Rudolf Pieber; Dhavalkumar D Patel Journal: J Allergy Clin Immunol Date: 2016-08-05 Impact factor: 10.793
Authors: Inge M G J Bronckers; Finola M Bruins; Maartje J van Geel; Hans M M Groenewoud; Wietske Kievit; Peter C M van de Kerkhof; Marcel C Pasch; Elke M G J de Jong; Marieke M B Seyger Journal: Acta Derm Venereol Date: 2019-02-01 Impact factor: 4.437
Authors: Helen He; Robert Bissonnette; Jianni Wu; Aisleen Diaz; Etienne Saint-Cyr Proulx; Catherine Maari; Carolyn Jack; Maudeline Louis; Yeriel Estrada; James G Krueger; Ning Zhang; Ana B Pavel; Emma Guttman-Yassky Journal: J Allergy Clin Immunol Date: 2020-07-21 Impact factor: 10.793
Authors: Guy H M Stanley; Katie Wang; Patrick Daly; Christopher Lau; Aoife M O'Brien; Cheryl Hamill; Mark Fear; Fiona M Wood Journal: Wound Repair Regen Date: 2022-06-17 Impact factor: 3.401